Vyteris, Inc. Announces Hiring of Specialty Sales and Marketing Team for Commercialization of LidoSite(R).

Physician Offices Can Begin Ordering LidoSite[R] At 888-VYTERIS

FAIR LAWN, N.J. -- Vyteris, Inc. (OTCBB: VYHN) kicked off the nationwide commercial availability of its LidoSite[R] transdermal patch with the deployment of a specialty sales and marketing team dedicated to the promotion and sale of LidoSite into targeted physician specialty offices, including rheumatologists, oncologists, and dermatologists.

LidoSite provides patients with rapid pain relief from procedures involving venipuncture, intravenous cannulation and laser ablation of superficial skin lesions. To head up the sales and marketing efforts, the hiring of Eric Pluckhorn as senior vice president of sales and marketing was also announced.

"The retention of an experienced pharmaceutical and medical device sales force marks our nationwide launch into the highly lucrative physician office market for LidoSite," said Timothy J. McIntyre, president and chief executive officer for Vyteris, Inc. "We believe the market for LidoSite is robust with patients, physicians and nurses looking for an effective alternative to topical cream anesthetics and distraction techniques to avoid pain associated with venipuncture/needle pain."

With more than one billion blood draws taken a year in the U.S.,1 a recent study by market research firm TVG, Inc. found that approximately 40 million patients a year experience "high discomfort" with blood draws due to needle pain.2

An overwhelming majority of the surveyed patients who experienced "high discomfort" - 65 percent in this case - indicated they intended to use or ask for LidoSite at their next blood draw; a potential U.S. market for LidoSite of 26 million patients annually.

The new specialty sales and marketing team will include specialty sales representatives and management positions to support physicians and their staffs in training on LidoSite, and in-service specialists. This exclusive team will work alongside Laboratory Corporation of America[R] Holdings (LabCorp[R]) (NYSE:LH), Vyteris' marketing partner in the general practice physician office market.

"I look forward to the opportunity to guide the sales growth and adoption of LidoSite into physician offices where we believe it can become a preferred treatment prior to cannulation procedures such as blood draws, venipuncture, IV catheter insertions or use prior to superficial dermatological procedures," Pluckhorn said. "We have assembled a talented and strong sales team of experienced professionals who are eager to implement our marketing effort."

In another recent clinical study by INC Research3, more than half of rheumatology physicians surveyed found LidoSite exceeded their expectations with regard to positively impacting their patient's experience. Overall, the majority of physicians in the study were satisfied with the LidoSite Topical System in its ease of use and conformity to standard office practices for rheumatology treatment applications.

LidoSite is the first active transdermal patch approved by the U.S. Food and Drug Administration to deal with pain associated with venipuncture for injections, intravenous cannulation for blood draws and laser ablation of superficial skin lesions. The device uses the process of iontophoresis to carry a combination of the pain killer lidocaine and epinephrine, which localizes the anesthetic effect, from a patch through the skin layer and into the underlying tissue by way of a mild electrical current.

LidoSite is composed of a heart-shaped controller housing a microprocessor regulating dosing of medication, intervals and duration of dosing and is good for up to 99 patch applications. Physicians interested in ordering LidoSite or receiving more information, can call 888-VYTERIS (898-3747) or go to www.vyteris.com/lidosite.

Eric Pluckhorn

Pluckhorn, 41, has been involved in virtually every aspect of pharmaceutical sales and marketing, as well as strategic planning and tactical execution, including launching brands such as Aranesp([R]), Neulasta([R]), Lupron Depot([R]), and Prevacid([R]). Over the course of his career, he has worked for TAP Pharmaceuticals, ViroPharma Inc., and Amgen USA.

Most recently, he held a senior management position within Euro RSCG Life, a leading healthcare advertising agency and part of the Euro RSCG network, the world's fifth-largest global advertising agency network. His successful experience in sales, training, product management and healthcare advertising for several billion-dollar products gives him a singular insight into the most effective strategic and tactical challenges across a wide footprint of therapeutic areas.

He received a Bachelor of Science degree in general engineering from the Unites States Military Academy at West Point. His career in pharmaceutical sales and marketing began after leaving the United States Army in 1992, where he served as an infantry officer. He is married with three children.

Aranesp([R]) and Neulasta([R] )are registered trademarks of Amgen. Lupron Depot([R]) and Prevacid([R]) are registered trademarks of TAP Pharmaceutical Products, Inc. LidoSite([R] )is a registered trademark of Vyteris, Inc.

About Vyteris, Inc.

Vyteris, Inc., a wholly owned subsidiary of Vyteris Holdings (Nevada), Inc. (OTCBB: VYHN), is the maker of the first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration (FDA). Vyteris' proprietary active transdermal drug delivery (iontophoresis) technology delivers drugs comfortably through the skin using low-level electrical energy. This active patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that can result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. Vyteris' first product, LidoSite([R]), which provides dermal analgesia prior to venipuncture (IV catheter insertions, blood draws, etc.) and superficial dermatological procedures, was the first FDA approved active patch. For more information, please visit our website at www.vyteris.com.

Forward-Looking Information

This press release contains forward-looking statements (within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended). When used in this press release, the words "anticipate," "believe," "estimate," "will," "plan," "seeks," "intend," and "expect" and similar expressions identify forward-looking statements. Although we believe that our plans, intentions, and expectations reflected in any forward-looking statements are reasonable, these plans, intentions, or expectations may not be achieved. Our actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied, by the forward-looking statements contained in this press release. Important factors that could cause actual results to differ materially from our forward looking statements are set forth in the Company's periodic reports on Forms 10-KSB and 10-QSB, including under the heading "Risk Factors." All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's periodic reports. Except as required by federal securities laws, we are under no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Important Safety Information

The LidoSite topical system is indicated for use on normal intact skin to provide local analgesia for superficial dermatological procedures such as venipuncture, IV cannulation, and laser ablation of superficial skin lesions. The LidoSite system is indicated for use on patients 5 years of age and older.

The LidoSite system is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type, sulfites, or to any other component of the product. It is also contraindicated for use in patients with electrically-sensitive devices (e.g., pacemakers) and should not be used on areas of the body supplied by end arteries or having otherwise compromised blood supply.

Iontophoresis with the LidoSite patch may cause local transient skin irritation such as blanching or erythema in the dermis under the patch. Patients over 65 years of age may have greater sensitivity to the LidoSite patch than younger patients.

The potential exists for a small child to suffer serious adverse effects from chewing or ingesting a new or used LidoSite patch. Children should be closely observed when treated with the LidoSite system, and LidoSite patches should be stored and disposed of in the proper manner.

Please refer to the full Prescribing Information, including the detailed instructions for use, before using the LidoSite topical system.

To receive regular email updates, please click (http://www.vyteris.com/home/Contact_Us/index.php)

To watch a video on how LidoSite works, please click (http://www.vyteris.com/home/Our_Technology/MOA.php)

1 LabMedicine, Vol. 36, No. 7, July 2005, pp. 430-433

2 TVG, Inc., November 2006, 1,010 respondents, +/- 3.5 percent

3 INC Research, Clinical Phase IV Open Label trial, 2007, Online: www.incresearch.com